Nicholas Smith, PhD

Nicholas Smith has more than 20 years of drug discovery experience in the pharmaceutical industry. Most recently at Metacrine Inc., he was a Senior Vice-President of Chemistry and oversaw the chemistry, DMPK and Intellectual Property groups.

Prior to Metacrine, he was at Seragon Pharmaceuticals and Aragon Pharmaceuticals, where he was Vice President of Chemistry and oversaw medicinal chemistry projects, including the development of two estrogen receptor degrader clinical candidates, and a next-generation androgen receptor antagonist program. In addition, Dr. Smith was responsible for the Aragon and then Seragon intellectual property portfolios and aspects of clinical manufacturing.

Prior to Aragon, he was Head of Chemistry at Kalypsys Pharmaceuticals. Prior to Kalypsys, Dr. Smith was a Research Fellow at Merck & Co., where he led chemistry groups that contributed to clinical candidates in the areas of obesity and inflammation.

Kevin Rosenthal

Kevin has nearly 30 years of pharmaceutical industry experience. Over his career, Kevin has successfully launched and managed several CDMO business units focused on and IND enabling drug product development and GMP clinical manufacturing within the US and Canada.  Kevin initiated his career with Dura and Elan Pharmaceuticals developing inhaled drug products before transitioning to various CDMO leadership positions, including at Pharmatek/Catalent and Eurofins Canada, where he established and led profitable CDMO business units.  Additionally, Kevin has designed and lead over 10 GMP facility build projects focused on oral drug product and clinical packaging operations in the US and Canada. Kevin is a graduate of San Diego State University with continuing education from the University of California San Diego.

Kimberly Ma, MS

Kim has over 17 years of clinical research experience in the biotech / pharmaceutical industry. Prior to joining RayzeBio, Kim served as Senior Vice President, Clinical Operations at Odonate Therapeutics where she led an in-house clinical operations team in running multiple clinical trials in metastatic breast cancer (Phases 1-3). From 2014 to 2017, Kim was Director, Clinical Project Management at Pfizer and led cross-functional teams for several early development trials in Pfizer’s oncology portfolio. Prior to Pfizer, Kim held positions of increasing responsibility at various CRO and Sponsor companies, including Medtronic Diabetes, ICON plc, and PPD.

Kim earned her Masters of Science in Regulatory Science from the University of Southern California (USC) School of Pharmacy and her Bachelors of Science in Biomedical Engineering from the USC Viterbi School of Engineering.

Rozalyn Littler

Rozalyn has over 20 years of drug development regulatory affairs and quality experience working previously at Metacrine, Heron Therapeutics, Genentech, MedImmune, and Johnson and Johnson, as well as an independent consultant.  Rozalyn’s experience has spanned all stages of drug development from pre-investigational new drug (IND) activities through new drug  application (NDA) submission, Advisory Committee, and post-approval.  She has worked on products such as Avastin®, Sustol ®, and CINVANTI®.  Rozalyn earned her Bachelors of Science in Engineering, Radiation Health Physics, from Oregon State University.

Kathie Huynh

Kathie has over 20 years of accounting and finance experience.  Prior to joining RayzeBio, she served as VP of Finance at Metacrine, where she led the buildout of the accounting and finance infrastructure and was involved in the preparation efforts of its initial public offering.  Prior to Metacrine, she served as VP of Finance at Biotix where she led all aspects of accounting and finance operations and was involved in the business development efforts resulting in its acquisition by Mettler Toledo.  Prior to Biotix, she served in various accounting positions with increasing responsibilities at Zogenix, Metabasis and Discovery Partners International.

Kathie is a certified public accountant (inactive) and holds a B.S. in Business Administration (Finance) from San Diego State University.

Eric Bischoff

Eric has a strong multidisciplinary background in metabolic disease and oncology targets with over 20 years of experience in the biotech/pharmaceutical industry. Prior to joining RayzeBio, he served as Vice President Development & Operations at Metacrine, Inc. a mid-stage clinical development company where he oversaw nonclinical development of the lead clinical assets for non-alcoholic steatohepatitis (NASH). Prior to Metacrine, he served as Senior Director of Operations at Seragon Pharmaceuticals and was involved in business development efforts resulting in the $1.7B acquisition of Seragon by Genentech, for an upfront payment of $725M and $1B in contingent development milestones. Prior to Ser agon, he served as Director of Operations at Aragon Pharmaceuticals on the development of apalutamide which was successfully commercialized following Aragon’s acquisition by Johnson & Johnson for $1B. In previous positions, Eric worked as a pharmacologist with numerous scientific publications on oncology and metabolic disease targets at companies including X-Ceptor Therapeutics, acquired by Exelixis, Ligand Pharmaceuticals and Hybritech, Inc. Eric is a graduate of the University of California at San Diego.

Abhi Bhat, PhD

Abhi has over 20 years of broad cross functional drug discovery experience spanning bio-conjugates, small molecules, and peptides across multiple therapeutic areas. Most recently, Abhi was the Sr. VP and Head of R&D at Design Therapeutics where he oversaw medicinal chemistry, biology, CMC and formulation functions and delivered the lead clinical asset for treatment of Friedrich ataxia along with a preclinical pipeline of GeneTAC™ molecules for treating nucleotide repeat disorders.   Abhi was previously the CSO at Pyramid Biosciences where he oversaw the development of two distinct Trk-Kinase inhibitors currently in clinical development for oncology and dermatology indications.  Prior to Pyramid, Abhi held R&D leadership roles at Ipsen, Redwood, Pfizer and CovX where he led projects from concept validation through early clinical development in oncology, metabolic diseases, pain and inflammation. Abhi received his PhD from The Ohio State University and conducted postdoctoral research at the Univ. of Arizona.

Ben Hickey

As president, Ben is responsible for the leadership of RayzeBio including the strategic growth of the company’s differentiated actinium-based radiopharmaceutical platform to enable rapid development of programs and therapies for the benefit of patients around the world. 

With over 20 years of industry experience, Ben joined RayzeBio in 2024 following the acquisition of Mirati Therapeutics where he was most recently chief commercial officer and head of business development. Prior to Mirati, Ben was senior vice president, chief commercial officer at Halozyme Therapeutics, where he was responsible for the global commercial strategy for the company’s oncology portfolio. Previously, Ben spent 17 years at Bristol Myers Squibb in various roles, including general manager, UK & Ireland, where he oversaw an organization of more than 300 people, and vice president Marketing, Immuno-Oncology. Ben received both his MBA and B.S. in management from St. John’s University in Queens, New York.